The FDA announced the action on April 15, 2026 (Federal Register notice April 16), and the peptides come off the Category 2 list effective April 23, 2026
Exploiting the antioxidant-rich Houttuynia cordata Thunb., we investigated natural GR inhibitors
FDA compounding review On December 4, 2024, the FDA Pharmacy Compounding Advisory Committee (PCAC) reviewed AOD-9604 (free base) and AOD-9604 acetate against the 503A Bulks List
TB-500 (wound healing) TB-500 is listed as thymosin beta-4 fragment (LKKTETQ), evaluated for wound healing
Common Side Effects Injection site reactions Headache Flushing Mild fluid retention Metabolic and Hormonal Considerations Potential alterations in glucose metabolism Elevated IGF-1 levels Theoretical risk of promoting tumor growth in predisposed individuals Key Limitation Most safety data comes from: Pediatric GH deficiency populations Adults with endocrine disorders There is limited long-term data in healthy, high-performing athletes
